4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

10-Q - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

10-Q - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

EFFECT - Caribou Biosciences, Inc. (0001619856) (Filer)

DEFA14A - Caribou Biosciences, Inc. (0001619856) (Filer)

S-3 - Caribou Biosciences, Inc. (0001619856) (Filer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

4 - Caribou Biosciences, Inc. (0001619856) (Issuer)

Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously

Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral

Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00

Truist initiated coverage of Caribou Biosciences with a rating of Buy and set a new price target of $23.00

RBC Capital initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $22.00

Brookline Capital initiated coverage of Caribou Biosciences with a rating of Buy and set a new price target of $19.00

Oppenheimer initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $36.00

H.C. Wainwright initiated coverage of Caribou Biosciences with a rating of Buy and set a new price target of $28.00

Citigroup upgraded Caribou Biosciences from Neutral to Buy and set a new price target of $27.00

Citigroup initiated coverage of Caribou Biosciences with a rating of Neutral and set a new price target of $27.00

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will host an expert physician panel discussion during an ancillary event at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The session will focus on how vispa-cel, Caribou's allogeneic anti-CD19 CAR-T cell therapy, has the potential to expand patient access by enabling readily

Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for LBCLCB-011 CaMMouflage phase 1 data demonstrate deep, durable responses and manageable safety, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for r/r multiple myeloma$159.2 million in cash, cash equivalents, and marketable securities as of September 30, 2025 BERKELEY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today r

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: 2025 Truist Securities BioPharma Symposium, New YorkNovember 6, 2025 8th Annual Evercore Healthcare Conference, Coral Gables, FLDecember 2, 2025 with fireside chat at 8:45-9:05 AM ETWebcast For more information and links to webcasts, please visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35) 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (N=22)86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient settingData highlight vispa-cel's potential as best-in-class allogeneic CAR-T cell therapy for LBCLConference c

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new data from the ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) and report the first clinical data from the CaMMouflage Phase 1 clinical trial evaluating CB-011, an allogeneic anti-BCMA CAR-T cell therapy, in patients with r/r multiple myeloma. The

BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to deve

-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan into H2 2027 -- BERKELEY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter 2025 and provided a business update for its oncology clinical programs CB-010 and CB-011 with data disclosures on track for H2 2025. "Caribou is advancing allogeneic CAR-T cell programs to deliver off-the-shelf therapies designed for rapid

BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the webcast, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transforma

-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its lead oncology clinical programs CB-010 and CB-011 with data disclosure for each planned for H2 2025. "Caribou's two lead Phase 1 clinical programs, CB-010 for large B cell lymphoma and CB-011 for

BERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communications functions. He will report to Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "I am excited to welcome Sri to Caribou at the beginning of this pivotal year for our organiz

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New Yo

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki brings over 20 years of experience leading human resources in the biotechnology industry. She will lead Caribou's people strategy and report to Rachel Haurwitz, PhD, president and chief executive officer. "Reigin is an experienced human resources leader who has an impressive track record in leading human resource strategies that are closely aligned with the mission, values, and culture of an organization,"

-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Stephen J. Schuster, MD, to its scientific advisory board (SAB). Dr. Schuster is an expert in treating patients with lymphoma and developing novel treatments, including pioneering the development of chimeric antigen receptor (CAR)-T cell therapies. "It's an honor to have Dr. Schuster join our SAB. Dr. Schuster is a highly esteemed global leader in the lymphoma field and played an integral part

BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical industry. "David has an impressive record of successfully building commercial infrastructure and launching new medicines for patients," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we contin

-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for patients with r/r multiple myeloma -- -- Leadership team expanded with appointment of Syed Rizvi, M.D., as chief medical officer -- -- Cash, cash equivalents, and marketable securities of $413.5 million as of December 31, 2021 support advancement of wholly owned pipeline of allogeneic CAR-T and CAR-NK cell therapies -- BERKELEY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU),

BERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer. Dr. Rizvi has more than two decades of experience in all stages of drug development, from clinical strategy and execution through regulatory submissions to support approval and commercialization of several cancer treatments, including two autologous CAR-T cell therapies ABECMA® and BREYANZI®. "Syed's extensive industry knowledge, strategic insight, and significant leadership experience in the development of oncology c

BERKELEY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointments of Dara Richardson-Heron, M.D., to its board of directors and Ruhi Khan as its chief business officer. Dr. Richardson-Heron has more than 25 years of leadership experience in the healthcare, corporate, nonprofit, and government sectors. Ms. Khan brings over 20 years of business development and investment management experience focused on the biotechnology and pharmaceutical industries. "Dara and Ruhi join Caribou at an exciting time as we advance our four wholly-owned allogeneic cell thera

SC 13D/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 202692% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimenConference call and webcast scheduled for today at 8:00 am ET BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first clinical data

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on patients who received optimized vispa-cel (N=35) 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort (N=22)86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile (N=35) Vispa-cel is generally well-tolerated, allowing for administration in the outpatient settingData highlight vispa-cel's potential as best-in-class allogeneic CAR-T cell therapy for LBCLConference c

-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases -- -- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 -- -- Conference call and webcast scheduled for today at 5:00 pm ET -- BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, t

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date -- -- LBCL patient subgroup had a 50% CR rate at ≥6 months; 18 months is the longest LBCL subgroup CR maintained to date -- -- Actively enrolling second-line LBCL patients in ANTLER dose expansion -- -- Conference call and webcast scheduled for today at 4:30 pm ET -- BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-s

-- 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- First patient treated in the ANTLER trial remained in CR at 12 months -- -- Based on promising initial safety profile and clinical activity, ANTLER Phase 1 trial enrolling patients at dose level 2 -- -- CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve the persistence of antitumor activity -- -- Caribou webcast conference call planned for today at 8:00 am ET -- -- Additional ANTLER data expected by year-end 2022 --

BERKELEY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the company will host a webcast conference call to share additional initial clinical data from its ANTLER Phase 1 clinical trial of CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) on Friday, June 10, 2022, at 8:00 am ET. The discussion will include longer duration data on the six patients treated at dose level 1 based on a new data cutoff date. Webcast presenters will include: Rachel Haurwitz, Ph.D., president and chief executive officer, CaribouSyed Rizvi, M.D., c

-- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- CB-010 is the 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5 of 5 patients) -- -- Based on promising initial safety profile, ANTLER Phase 1 trial enrolling patients at dose level 2 -- -- CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve the persistence of antitumor activity -- -- Caribou webcast conference call planned for today at 10:15 am ET -- -- Initial data scheduled to be shared at the European Hematology Association (EHA) 2022 Co